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  33 
Abstract (248 words) 34 
Optical coherence tomography angiography (OCTA) has emerged as a 35 
novel, non-invasive imaging modality that allows the detailed study of 36 
flow within the vascular structures of the eye. Compared to 37 
conventional dye angiography, OCTA can produce more detailed, 38 
higher resolution images of the vasculature without the added risk of 39 
dye injection. In our review, we discuss the advantages and 40 
disadvantages of this new technology in comparison to conventional 41 
dye angiography. We provide an overview of the current OCTA 42 
technology available, compare the various commercial OCTA machines 43 
technical specifications and discuss some future software 44 
improvements. An approach to the interpretation of OCTA images by 45 
correlating images to other multi-modal imaging with attention to 46 
identifying potential artefacts will be outlined and may be useful to 47 
ophthalmologists, particularly those who are currently still unfamiliar 48 
with this new technology.  49 
 50 
This review is based on a search of peer-reviewed published papers 51 
relevant to OCTA according to our current knowledge, up to January 52 
2017, available on the PubMed database. Currently, many of the 53 
published studies have focused on OCTA imaging of the retina, in 54 
particular, the use of OCTA in the diagnosis and management of 55 
common retinal diseases such as age related macular degeneration and 56 
retinal vascular diseases. In addition, we describe clinical applications 57 
for OCTA imaging in inflammatory diseases, optic nerve diseases and 58 
anterior segment diseases. This review is based on both the current 59 
literature and the clinical experience of our individual authors, with an 60 
emphasis on the clinical applications of this imaging technology. 61 
 62 
  63 
Method 64 
This comprehensive literature review was performed based on a 65 
search of peer-reviewed published papers relevant to optical 66 
coherence tomography angiography (OCTA) according to our current 67 
knowledge, up to January 2017, available on the PubMed database. 68 
This review will highlight OCTA technology and software updates 69 
relevant to clinicians and discuss clinical approaches to the 70 
interpretation of OCTA keeping in mind its limitations and artefacts. 71 
We will then examine some current clinical applications of this 72 
technology and implications for future use. 73 
 74 
Overview of technology  75 
 76 
OCT angiography (OCTA) is a novel imaging modality that allows the 77 
detailed 3 dimensional study of blood flow within the vascular 78 
structures of the eye without the need to intravenously administer 79 
fluorescent dyes.1,2    OCTA technology is based on detecting 80 
differences in amplitude, intensity or phase variance between 81 
sequential B-scans taken at the same location of the retina.1 Briefly, a 82 
series of B-scans are collected at the same transverse location and 83 
registered. The degree of decorrelation in signal is then calculated, 84 
which enables visualization of only the moving part, assumed to be due 85 
to movement of cells within the blood stream and thus blood flow. The 86 
above procedure is then repeated for different Y-position in the retina 87 
to achieve the 3D dataset, from which proprietary algorithms such as 88 
split-spectrum amplitude-decorrelation angiography (SSADA), optical 89 
microangiography (OMAG) and OCT angiography ratio analysis 90 
(OCTARA) are used to reconstruct enface angiograms (Figure 1).  91 
OCTA offers several advantages compared to conventional 92 
angiography. The non-invasive nature and fast acquisition time allows 93 
this test to be repeated frequently and avoids the potential risks 94 
associated with intravenous dye injection (Table 1). In addition, high-95 
resolution details of the vasculature and depth-resolved analysis, in 96 
which the flow within a specific axial location of the retinal or choroid 97 
can be analysed(Table 1). The absence of functional information such 98 
as the severity of exudation and filling speed as well as stereoscopic 99 
viewing and wide-field functions (Table 1) are other disadvantages of 100 
OCTA compared to conventional angiography. 101 
Automated, objective quantitative measures (angio-analytics) of flow 102 
have been incorporated into many OCTA platforms (Table 2.)3 These 103 
software developments are still in their infancy and need to be tested 104 
for intra- and inter-platform reliability and repeatability, in both 105 
normal and diseased eyes Some instruments offer a function to 106 
‘register’ two different visits by aligning features on the enface images. 107 
This function is useful for assessing treatment response and disease 108 
progression  (Table 2).4-7  109 
OCTA interpretation and potential artefacts  110 
In our experience, high quality image acquisition for each OCTA 111 
platform has a learning curve; hence good technical support is 112 
essential and poor quality images should be identified. Instrument-113 
related factors that may affect image quality include differences in 114 
acquisition time. Patient-related factors include age, ability to co-115 
operate and maintain fixation, and the presence media opacity. 116 
Similar to image acquisition, OCTA interpretation by the clinician, also 117 
has a learning curve. The user interfaces of most of the current OCTA 118 
platforms vary, however the basic components are similar. An 119 
approach to OCTA interpretation is outlined below (Figure 2). 120 
• Assess the scan quality 121 
This should include assessment of the scan centration, resolution and 122 
signal strength. Signal strength may be affected by patient co-123 
operation, fixation or medial opacity. 124 
• Identify the layer and the area of interest 125 
 126 
Through a detailed clinical exam and examination of the structural 127 
OCT, the clinician should be able to determine at which layer (retinal 128 
versus choroidal) the pathology lies and the area of interest to be 129 
scanned by the OCTA, keeping in mind the various scan area options 130 
available on the various OCTA platforms. If the pathology is not around 131 
the macula, an OCTA scan decentred from the fovea may be necessary.  132 
 133 
• Examine the cross-sectional OCTA for abnormal flow 134 
Most OCTA platforms represent the detected flow signals by 135 
superimposing them onto a structural B-scan OCT images in a coloured 136 
overlay to derive a cross sectional OCTA image (Figure 1). Scrolling 137 
through the cross-sectional OCTA images to look for abnormal flow in 138 
the layer and area of interest will help locate the corresponding area 139 
on the enface OCTA to focus on. 140 
• Choose the preset segmentation pattern that best captures the area of 141 
abnormal flow  142 
 143 
All the commercially available OCTA instruments are built with 144 
automated segmentation (Table 2). If no particular segmentation 145 
pattern is able to accurately capture the area of abnormal flow, (e.g. for 146 
studying large choroidal vessels or pre-retinal neovascularization), 147 
customized segmentations patterns may be necessary to obtain an 148 
optimized en face OCTA image. 149 
 150 
• Manual manipulation of the segmentation to optimise the en face 151 
OCTA image 152 
The exact depth and thickness of the preset segment varies according 153 
to individual instrument. Further manual adjustment of the lower and 154 
the upper boundaries of various segmentation patterns will allow the 155 
enface OCTA image to be easily tailored towards the clinical question. 156 
In some pathological cases, where the anatomy is severely disrupted, 157 
automated segmentation may not be accurate and the adjustment of 158 
the contour on each of the individual B scan segmentation lines may be 159 
required to optimize the en face OCTA image (Figure 3D). This manual 160 
adjustment of the contour is both time and labour intensive. However 161 
upgrades in the software, such as auto-propagation of manual changes 162 
have shortened the time to perform such adjustments may improve 163 
this function. 164 
Correlate to other imaging modalities 165 
OCTA is a new technology, which has yet to be validated; hence 166 
interpretation should be done with caution and in equivocal cases 167 
correlation with more conventional modalities such as fundus 168 
fluorescein angiography (FA) or indocyanine green angiography 169 
(ICGA). 170 
• Be mindful of artefacts 171 
Understanding the types and sources of artefacts is important during 172 
the interpretation of OCTA (Figure 3).8,9 Motion artefacts caused by 173 
blinking results in dark lines, while motion artefacts due to saccadic 174 
eye movements or bulk movements usually appear as horizontal white 175 
lines and can be minimized with a few strategies such as orthogonal 176 
image registration (Figure 3A),9,10 the incorporation of an eye-tracker 177 
or a combination of tracking assisted scanning integrated with motion 178 
correction technology (Table 2).11 In theory, less motion artefact 179 
should occur with a more sensitive the eye-tracker; however a highly 180 
sensitive eye tracker may increase the acquisition time and make 181 
imaging challenging. 182 
As previously stated, segmentation errors are common in pathology, in 183 
which the retinal architecture is altered. Inaccurate segmentation may 184 
result in dark areas on the enface OCTA image (Figure 3D). Scrolling 185 
through the structural OCT volume scan will allow identification of 186 
areas with inaccurate segmentation. Manual adjustment should be 187 
performed before interpretation of the final en face OCTA. 188 
Projection artefacts occur in highly reflective layers of the retina such 189 
as the retinal pigment epithelium (RPE) (Figure 3B). 8,9,12,13 When 190 
superficial retinal flow signals (Figure 3B-green box) are reflected off 191 
the deeper layers, they will be detected as decorrelation signals that 192 
possess the same character as overlying blood vessels. (Figure 3B-193 
yellow box).12 As a result, flow may be inaccurately interpreted to be 194 
present within a deeper structure, when the flow signals actually 195 
originated from the more superficial layers. Most OCTA platforms 196 
possess in-built software to mask the projection artefacts in the outer 197 
retinal layers. 14 However, this software has limitations, as projection 198 
artefacts may occur in various other layers, especially in 199 
hyperreflective pathological structures such as hard exudates and 200 
subretinal fibrosis. 14,15A useful way to ascertain whether the flow 201 
signal seen is due to projection artefact is by examining the cross 202 
sectional OCTA (or Angio B scan), in which the linear signals can be 203 
traced to flow within a more superficial layer (Figure 4).  204 
Masking artefacts in the choroidal layers may be caused by blocked 205 
flow signals from overlying hyper-reflective structures, slow flow, 206 
which is below the detectable threshold or a possible segmentation 207 
error.13,15 On the other hand, unmasking artefacts are seen when areas 208 
of RPE atrophy allow the back-scatter, decorrelation signal of the 209 
underlying choroidal vessels to be seen as areas of increased flow 210 
within the choroid (Figure 3C). 13 On cross sectional OCTA, the high 211 
flow signal is seen directly under the areas where the hyperreflective 212 
RPE band is disrupted (Figure 3C). On en face OCTA, the boundaries of 213 
the high flow area sharply correspond to the areas of RPE loss and this 214 
a further confirmed on comparison to fundus autofluorescence (FAF), 215 
where the high flow area corresponds to the area of 216 
hypoautofluorescence due to RPE atrophy (Figure 3C). Other artefacts 217 
described such as the fringe washout effect and the stromal 218 
decorrelation signal, may help explain the differences in the vascular 219 
appearance in normal eyes of the choroidal vessels, which appear dark 220 
compared to the surrounding stroma versus retinal vessels that appear 221 
bright.13 222 
 223 
OCTA in age related macular degeneration and other choroidal 224 
diseases  225 
Many studies have evaluated OCTA in the diagnosis and monitoring of 226 
treatment response in neovascular AMD.  227 
 228 
OCTA findings in choroidal neovascularization (NV) 229 
 230 
Type 1 NV 231 
OCTA may allow better visualization of the vascular structure of the 232 
type 1 NV compared to FA, as there is less masking from the overlying 233 
RPE and the vasculature is not obscured by dye leakage. 16 The OCT 234 
appearance of a type 1 NV is characterised by a vascularised pigment 235 
epithelial detachment (PED) with an irregular surface and 236 
hyperreflective contents. On cross sectional OCTA, intrinsic flow is 237 
seen within the contents of the PED in the sub-RPE space (Figure 4A).17 238 
In the corresponding enface OCTA, typically, type 1 NV appears as a 239 
well-defined tangle of vessels (Figure 4A).17-19 Compared to FA, 240 
previous retrospective case series have reported that OCTA can detect 241 
Type 1 NV in 67-100% of cases.18-20 Compared to mid- or late phase 242 
ICGA, the appearance of Type 1 NV on OCTA has been noted to occupy 243 
significantly smaller areas.21  244 
 245 
Type 2 NV 246 
An active type 2 NV appears as subretinal hyper-reflective material 247 
(SHRM) above the RPE with intrinsic flow signals on cross sectional 248 
OCTA (Figure 4B)15,22. The hyper-flow patterns detected, that were 249 
described as either a glomerulus or a medusa shape, were associated 250 
with a thicker main vessel branch connected to the deeper choroid.22 A 251 
dark halo surrounding the lesion was thought to correspond to 252 
masking from surrounding, blood, exudation or subretinal fibrosis.22 Of 253 
note, the high flow signal was also shown in some cases to cause a 254 
projection artefact onto the deeper choriocapillaris layer.22 255 
 256 
Mixed type 1 and type 2 lesion can be observed as abnormal flow seen 257 
both above and below the RPE on cross sectional OCTA (Figure 6B).23 258 
By varying the depth of segmentation, both the more superficial 259 
subretinal type 2 component and the deeper sub-RPE type 1 260 
component can be seen on en face OCTA as a vascular network. A 261 
previous paper described a larger decrease in the area of the type 2 262 
component compared to the type 1 component in response to anti-263 
VEGF therapy.23 264 
 265 
Retinal Angiomatous proliferation (Type 3 NV) 266 
 267 
Typical OCT findings of type 3 NV show a linear hyper-reflective 268 
structure extending from the outer retina to the inner retinal layers, 269 
with or without PED. Cross-sectional OCTA of type 3 NV showed 270 
intrinsic flow within this structure and 2 patterns of flow were 271 
observed; either a discrete intra-retinal flow signal or a linear flow 272 
signal that extended from the intra-retinal areas deep through to the 273 
RPE band (Figure 4C).24 En face OCTA of the type 3 NV, showed a 274 
bright high flow tuft of microvessels originating from the deep 275 
capillary plexus in the outer retina.24,25 Distinct neovascular complexes 276 
could only be imaged in 34% of eyes, all of which showed signs of 277 
activity on OCT.25,26 278 
 279 
Progression of neovascularization in response to treatment 280 
Various terminologies have been proposed to describe features that 281 
reflect different stages or level of activity within a neovascular 282 
network.  However, there is lack of standardization and validation, so 283 
these terms are likely to undergo further refinement. While OCTA 284 
cannot evaluate the presence of leakage or exudation, changes in 285 
pattern of vasculature on OCTA have been reported as the NV evolves 286 
from active to inactive stages. Characteristic features suggestive of an 287 
active NV include presence of a tangle of vessels in a well-defined 288 
shape (lacy-wheel or sea fan), branching, numerous tiny capillaries, the 289 
presence of anastomoses or loops, the presence of a peripheral arcade 290 
and the presence of a hypointense halo (Figure 5B).27 In contrast, 291 
inactive chronic NVs have larger more mature vessels, a “dead tree” 292 
appearance with the absence of the anastomoses, loops and peripheral 293 
arcades.27After intravitreal anti-VEGF therapy NV showed a decrease in 294 
vessel density, vessel fragmentation and the loss of peripheral 295 
capillaries after 1 week with recurrence of the peripheral anastomosis 296 
and increased capillary density at 4 weeks.28 29 Finally, chronic NV may 297 
show little anatomical response to anti-VEGF (Figure 5B)18. On OCTA, 298 
the lesion area and vessel density have been observed to remain 299 
unchanged and the vascular tangle may develop a pruned tree 300 
appearance.18,25 These fibrovascular PEDs that had undergone multiple 301 
previous treatments, demonstrated prominent vascular loops and 302 
anastomotic connections and showed trunk feeder vessels of a large 303 
diameter with limited branching patterns.30  304 
 305 
In response to anti-VEGF therapy, type 3 NVs on OCTA showed a 306 
significant regression in the small calibre tufts in all eyes, with a 307 
reduction in median lesion area and exudation.6,26 In 29% of eyes, the 308 
high flow lesion became undetectable after a single intravitreal anti-309 
VEGF injection, however in 65% of eyes there was persistence of the 310 
large feeder vessels.6 Longitudinal imaging of type 3 NV also showed 311 
that OCTA could detect changes in the vascular complex even before 312 
the presence of exudation seen on OCT, and this may represent early 313 
recurrence. It was also noted that OCTA enabled the distinction 314 
between hyper-reflective vascular structures of the type 3 NV from 315 
other surrounding hyper-reflective foci devoid of flow, which may 316 
correlate to pigment migration.5 317 
 318 
OCTA findings in polypoidal choroidal vasculopathy (PCV) and 319 
other pachychoroid conditions 320 
 321 
ICGA is a useful modality for diagnosing PCV. Previous studies show 322 
that OCTA is comparable to ICGA for the detection of BVN.31-36 In 323 
contrast, the rate of polyp detection by OCTA was much more variable 324 
ranging from 17-85%.33,34,36,37 Using cross-sectional OCTA, most 325 
studies report the BVN to be in the sub RPE space between the RPE 326 
and Bruch’s membrane,31-33,35 however in one study, some BVNs 327 
associated with PCVs were located deeper within the choroid (Figure 328 
6A)33. En face OCTA of the BVN often show networks of vessels in much 329 
more detail than ICGA (Figure 6A).31-36 Cross sectional OCTA of the 330 
polyp, showed patchy flow signals within the polyp with the lumen 331 
being largely devoid of flow signals. 31,33,35 Enface OCTA imaging of the 332 
polyps was reported to show a more common hypoflow round 333 
structure (75%) or less common (25%) hyperflow round structure 334 
surrounded by a hypointense halo.36 Polyp area measured on OCTA 335 
was also noted to be consistently smaller when compared to ICGA.37 336 
Some authors hypothesize that the slow or turbulent flow within the 337 
polyp may explain the hypoflow appearance. 338 
 339 
One study using ss-OCTA imaging showed that in response to anti-340 
VEGF therapy and in some cases combined photodynamic therapy, 341 
there was a reduction in flow within the PCV complex in most eyes.34 In 342 
several eyes, despite the improvement in exudation, the ss-OCTA 343 
appearance of the vascular network was unchanged.34 Changes in the 344 
appearance of the vascular network, which may represent early 345 
recurrence on OCTA may occur even without significant changes on 346 
OCT.34 Despite quiescence of lesions, as determined on OCT by the 347 
absence of exudation, 88% showed the persistence of flow signals 348 
within the vascular network and this may be a risk factor for 349 
recurrence.34 350 
 351 
For all NVs and PCV, longitudinal changes in the flow detected on OCTA 352 
appeared to highly correlate with level of exudation assessed by 353 
structural OCT. In addition, many studies have now demonstrated that 354 
the flow signal often persists even though there is absence of fluid, or 355 
within a fibrosed scar. 38 356 
 357 
Additional OCTA findings in AMD 358 
 359 
Studies based on OCTA have reported that 6-15% of eyes with chronic 360 
CSC have an associated type 1 NV often seen as a shallow irregular 361 
PED.20,39 One study reported that OCTA was more sensitive at detecting 362 
vascularised PEDs associated with chronic CSC when compared to dye 363 
angiography.40 364 
 365 
Quiescent NV refers to NV detected on conventional angiography such 366 
as FA or ICGA, which shows the absence of exudation.41 FA shows an 367 
ill-defined hyperfluorescent lesion with no leakage, while ICGA shows 368 
the presence of a hypercyanescent “plaque”.41 OCTA was reported to 369 
have a sensitivity of 81.8% in quiescent NV detection.41 Another study 370 
examining eyes with intermediate AMD with the fellow eye having 371 
neovascular AMD, showed 27% of eyes with intermediate AMD had the 372 
presence of a “plaque” on ICGA and a corresponding network of vessels 373 
on ss-OCTA.42 Another similar study, showed 6% of eyes were found to 374 
have the presence of type 1 NV on OCTA, despite no leakage on FA and 375 
exudation on OCT.43 The clinical significance of these non-exudative, 376 
vascular networks remains to be determined and it has been suggested 377 
that they develop in response to retinal ischemia.  It has also been 378 
noted that some of these non-exudative networks will develop frank 379 
exudation during follow-up and thus represent the first signs of early 380 
CNV development. OCTA now provides a method to repeatedly image 381 
non-invasively these networks of dormant vessels and thus provide 382 
insights into the natural history of such lesions. 383 
 384 
In eyes with the presence of subretinal fibrosis secondary to 385 
neovascular AMD, 94% of eyes showed the presence of abnormal flow 386 
signals within the area of fibrosis.38 Further longitudinal studies are 387 
required to determine the significance of these findings. 388 
 389 
In early AMD, previous studies suggest there maybe a generalised 390 
reduction in choriocapillaris density compared to normal age matched 391 
controls.44 Due to the shadowing effect of drusen and PEDs, ss-OCTA 392 
has been suggested as the modality of choice due to better penetration 393 
and less shadowing.42-44 In advanced AMD with geographic atrophy 394 
(GA), due to a loss in the RPE and choriocapillaris, the changes in the 395 
underlying choroid are well seen on OCTA.44 Another study using ss-396 
OCTA, reported that both focal and diffuse choriocapillaris flow 397 
impairment occurred in eyes with both nascent GA and drusen 398 
associated GA.45 In addition to the choroidal circulation, AMD can also 399 
cause vascular density reductions in the superficial and deep retinal 400 
plexuses when compared to controls.46 401 
 402 
OCTA in eyes with high myopia 403 
OCTA imaging in eyes with pathologic myopia may help differentiate 404 
between complications such secondary choroidal neovascularisation 405 
where an abnormal flow is seen within the SHRM on cross-sectional 406 
OCTA corresponding to a hyper-flow vascular network seen on en face 407 
OCTA from a simple haemorrhage where no flow or vascular network 408 
is observed. 47 Previous studies have also indicated that in highly 409 
myopic eyes where general thinning of the retinal and choroidal layers 410 
are common, OCTA shows an overall reduced retinal capillary and 411 
choriocapillary density.48,49 However, OCTA imaging in eyes with high 412 
myopia is challenging due to the steep curvature of the staphyloma 413 
causing poor focus or segmentation errors, areas of myopic 414 
degeneration can also lead to unmasking artefacts and difficulty 415 
imaging choroidal flow.50 416 
 417 
OCTA in retinal vascular diseases  418 
OCTA in the imaging of vascular diseases has a few important 419 
applications. In the macular region, OCTA allows good delineation of 420 
the foveal avascular zone (FAZ) 51-54 and allows the detection of 421 
macular ischaemia and microaneurysms (Figure 7). In the peripheral 422 
retina, areas of capillary drop out and the detection of 423 
neovascularisation at the disc and elsewhere can also be imaged well 424 
on OCTA (Figure 8). 425 
 426 
Diabetic eye disease 427 
 428 
Microaneurysms can be identified in the superficial and deep retinal 429 
capillary plexi and appear as focally dilated saccular or fusiform 430 
capillaries (Figure 7A). Studies to-date suggest that there is often 431 
disagreement between identification of microaneurysm on OCTA and 432 
FA and even between different OCTA platforms.52 Not all 433 
microaneurysms seen on FA can be found on OCTA, and vice versa 434 
some of the dilated capillary changes on OCTA that resembled 435 
microaneurysms are not found FA.55 Most studies noted more 436 
microaneurysms on FA than OCTA52,56, however, Peres et al noted that 437 
OCTA of the DCP had more microaeurysms then either FA or the SCP 438 
on OCTA.  439 
 440 
Comparison of FA and OCTA has demonstrated that OCTA allows 441 
better discrimination of the FAZ and parafoveal microvasculature than 442 
FA, in particular for FAZ disruption, enlargement and capillary dropout 443 
52(Figure 7B). In diabetic retinopathy, the outline of the FAZ may 444 
become irregular, with enlarged perivascular spaces and disruption of 445 
the capillary ring. The increase in FAZ area, present in both the 446 
superficial and deep retinal plexi, can precede the development of 447 
clinical diabetic retinopathy, suggesting that diabetic eyes show 448 
impairment of the retinal microcirculation before retinopathy 449 
develops.57,58 The FAZ area was also found to increase with the 450 
presence of clinically significant macular oedema (Figure 7B), however 451 
there was no statistically significant difference in FAZ area between 452 
eyes with non-proliferative and proliferative diabetic retinopathy. It is 453 
important to note that variations in axial length can affect the retinal 454 
vessel magnification on OCTA. Adjustment can be made if axial length 455 
measures are available. Some strategies to quantify the irregularity of 456 
the FAZ independent of axial length include an acircularity index, 457 
defined as the ratio of the perimeter of the FAZ to the perimeter of a 458 
circle with an equal area and an axis ratio, defined as the ratio between 459 
the major and minor axis of an ellipse defined by custom software.53 460 
Krawitz et al demonstrated that both the acircularity index and axis 461 
ratio increase with diabetic retinopathy severity and may have 462 
potential to characterize disease severity.53 These structural changes 463 
on OCTA in diabetic eyes have also been correlated with function. 464 
Balaratnasingam et al described the correlation between larger FAZ 465 
area and worse visual acuity in eyes with diabetic retinopathy. Samara 466 
et al found that visual acuity also correlated with FAZ area, vessel area 467 
density and vessel length density on OCTA. 59 468 
 469 
OCTA can also identify neovascularization associated with diabetic 470 
retinopathy or retinal vein occlusions (Figure 8). Serial OCTAs can 471 
been used to monitor the change in area of disc neovascularization in 472 
response to treatment with anti-VEGF injections 60. When 473 
appropriately used, OCTA can also identify the presence of ischemia 474 
and neovascularization in the retina mid periphery; and differentiate 475 
new vessels which tend to be anterior to the internal limiting 476 
membrane, from collaterals and intra retinal microvascular 477 
abnormalities.61 478 
 479 
Quantitative tools have been developed to quantify areas of retinal 480 
perfusion on OCTA. Capillary fall out in the area surrounding the FAZ 481 
can be readily identified, and may exceed that identified on FA, as these 482 
areas can be masked by diffuse fluorescein leakage.62 Retinal 483 
vasculature on OCTA can be skeletonized or binarised to define the 484 
total capillary length or luminal area. Various measures of capillary 485 
density based on ratio of luminal area to total area have also been 486 
described.63-66 Good repeatability and reproducibility of FAZ area and 487 
capillary density on OCTA have been demonstrated in normal eyes.67 In 488 
normal eyes, with increasing age, capillary density was found to 489 
decrease while the FAZ area increases.67 Studies have consistently 490 
described lower capillary density in diabetic eyes compared with 491 
controls in both the deep and superficial layers. There was also a 492 
consistent trend of decreasing capillary density with retinopathy 493 
severity.63,64,66 Automated algorithms to detect the avascular area on 494 
OCTA was not only shown to be highly repeatable and reproducible 495 
with the coefficient of variation reported to be less than 7.0%63 but 496 
could also be used to distinguish mild NPDR from normal eyes.65 Other 497 
authors who have examined capillary density and vascular measures 498 
such as fractal dimension have also demonstrated a similar trend with 499 
severity of DR64,66. Ting et al also demonstrated that hyperlipidemia, 500 
smoking and renal impairment were associated with capillary density 501 
decrease while increased HbA1c and renal impairment were 502 
associated with a increased fractal dimension in diabetic eyes, 503 
suggesting the link between vascular risk factors and preclinical retinal 504 
microvascular changes seen on OCTA.66  505 
 506 
In diabetic macular oedema (DMO), OCTA has been used to assess the 507 
baseline characteristics as well as response to anti-VEGF injections 508 
(Figure 7B). Lee et al found that DMO eyes had more microaneurysms 509 
in the capillary plexus, a lower vascular flow density and a larger FAZ 510 
area in the DCP then eyes without DMO. DMO eyes, which were poor 511 
responders to anti-VEGF treatment had a significantly larger FAZ area 512 
and more microaneurysms in the deep capillary plexus on OCTA 513 
compared to eyes that responded well to anti-VEGF treatment. This 514 
suggests that the deep capillary plexus is important in DMO occurrence 515 
and may be a useful prognostic tool for predicting anti-VEGF treatment 516 
response in DMO. Another study examining OCTA in DMO did not 517 
demonstrate any change in FAZ area after the treatment of macular 518 
oedema with a single injection of anti-VEGF. 54 519 
 520 
Retinal vascular occlusions 521 
 522 
OCTA can be used to confirm the clinical diagnosis of both retinal vein 523 
and artery occlusions.68,69 Similar to its utility in DR, OCTA is able to 524 
identify capillary non-perfusion, retinal ischemia, collateral vessels, 525 
capillary telangiectasia and microaneurysms, in addition to delineating 526 
the FAZ in macular ischemia secondary to retinal vein occlusion (RVO) 527 
(Figure 8A&B).61,70 69,71-74 It has been noted that in RVO, the 528 
microvascular changes on OCTA are more prominent in the deep 529 
retinal plexus than in the superficial plexus.72 The FAZ area and vessel 530 
density on OCTA have been found to correlate with strongly with 531 
visual acuity in RVO both before and after treatment with anti-VEGF 532 
injections.75,76 70 OCTA has also been used to follow-up RVO after 533 
treatment, and demonstrated reduction of areas of non-perfusion and 534 
capillary disruption after treatment with anti-VEGF injections.77 In 535 
retinal artery occlusion (RAO), OCTA is able to delineate the extent of 536 
macular non-perfusion and follow-up changes in the vascular flow over 537 
time, and it also revealed perfusion defects in the superificial capillary 538 
plexus, which were not seen on FA.68 The development of 539 
neovascularisation in an ischaemic RVO can also be detected on OCTA 540 
(Figure 8C) 541 
 542 
Retinal vascular disease affects both the macular and the peripheral 543 
retinal vasculature, and therefore the constraints in imaging of the 544 
peripheral retina with OCTA will limit its utility. OCTA is also unable to 545 
identify areas of focal leakage unlike FA and is dependent on a 546 
cooperative patient with reasonable fixation to produce high quality 547 
images.  Segmentation in eyes with macular oedema can also be 548 
challenging and can affect the interpretation of the retinal capillary 549 
plexus, with as many as 22% of images being unreadable.54,59 550 
 551 
Macular telangiectasia 552 
In macula telangiectasia type 1 (MacTel1), a predominantly unilateral 553 
disease, previous studies have reported focal microvascular dilatation 554 
and both global and focal capillary depletion when compared to the 555 
fellow eye and normal controls.78 Volume rendered OCTA images of 556 
eyes with macula telangiectasia type 2 (MacTel2) suggested that the 557 
microvascular changes maybe due to vascular invasion and retinal 558 
thinning and secondary subretinal neovascularisation originate in the 559 
retinal circulation but could infiltrate both the subretinal space and the 560 
overlying thinned retina.79 The contraction of the tissue surrounding 561 
the temporal macula in the presence of stellate arranged vessels may 562 
explain the origin of the right-angle veins.80 OCTA was also able to 563 
study the progression of MacTel2 and showed that an increase in the 564 
inter-vascular spaces, capillary rarefaction and increasing abnormal 565 
areas of anastomosis was associated with a reduced capillary density 566 
in the superficial and deep layers when compared to controls.81,82 567 
 568 
OCTA in inflammatory diseases  569 
 570 
Imaging in inflammatory eye diseases has a number of key roles: (1) 571 
detection – i.e. to identify the presence of an inflammatory process; (2) 572 
diagnosis – i.e. to identify the type of inflammation; (3) monitoring – 573 
i.e. to evaluate disease activity and damage.83 Although OCTA has a role 574 
to play in all three domains, it is emerging as a particularly valuable 575 
tool in the area of monitoring. In particular, it is proving valuable in 576 
two key areas where other imaging techniques sometimes fall short: 577 
(1) the need to differentiate between active inflammatory lesions, 578 
active vascular lesions and inactive fibrotic lesions – highlighted by 579 
difficult treatment decisions in conditions such as Punctate Inner 580 
Choroidopathy (PIC); and (2) the need to quantify inflammatory 581 
activity, both to stratify treatment and to monitor response to 582 
treatment.  583 
 584 
Review of the literature in this field identifies short case series and 585 
individual case reports, many of which highlight the additional value of 586 
OCTA as part of a multimodal approach. Although no formal 587 
prospective trials to assess its diagnostic utility in uveitis are yet 588 
available, the studies discussed below show how particular clinical 589 
indications or disease groups may benefit from the additional 590 
information provided by OCTA.  591 
 592 
Clinical scenarios 593 
 594 
Uveitic Macular Oedema 595 
As one of the leading causes of sight loss in uveitis, uveitic macular 596 
oedema (UMO) is of particular interest, although some caution is 597 
required in OCTA interpretation as extensive oedema may hamper 598 
visualisation and induce artefact. Few studies are available thus far, 599 
but it is interesting to note that in an analysis of 25 eyes with UMO, 600 
Kim et al report significantly lower vessel density in the deep retinal 601 
plexus in eyes with UMO (vs non-UMO uveitic eyes).84 This preliminary 602 
evidence would support the hypothesis that the leakage in UMO is not 603 
entirely due to increased permeability from inflammatory mediators, 604 
but does include an ischaemic element.  605 
 606 
Retinal vasculitis 607 
Assessing disease activity in retinal vasculitis is challenging. It is 608 
usually based on FA with a particular regard to leakage, but also other 609 
vascular abnormalities such as progression of ischaemia. Specific 610 
limitations of FA in this context are (1) leakage of dye in FA may limit 611 
assessment of capillary ‘drop-out’ due to ischaemia, and (2) damaged 612 
retinal vasculature frequently remains leaky limiting reliable 613 
assessment of disease activity. OCTA has the advantages of being able 614 
to assess both structure and perfusion of the microvasculature without 615 
being obscured by leakage. It does have the disadvantage of not 616 
directly assessing leakage, which subject to the limitations above, may 617 
still be a useful indicator of active vasculitis. In an analysis of 61 uveitic 618 
eyes (including a number with retinal vasculitis) and 94 healthy eyes 619 
Kim et al report that the superficial retinal plexus showed reduced 620 
parafoveal capillary density and reduced branching complexity in 621 
uveitic versus healthy eyes; vessel calibre was also not significantly 622 
different between uveitic and healthy eyes.84 623 
 624 
Punctate inner chorioretinopathy (PIC)/ Multifocal choroiditis with 625 
panuveitis (MCP) spectrum 626 
A significant challenge in the care of patients with PIC or multifocal 627 
choroiditis with panuveitis (MCP) is to distinguish whether new 628 
lesions are inflammatory, neovascular or both (Figure 9). This has 629 
major therapeutic implications. OCT findings may be very similar in 630 
both inflammatory lesions and CNV arising from the inner 631 
choroid/RPE with sub-RPE and subretinal involvement; although CNV 632 
may have greater heterogeneity then inflammatory lesions this is not 633 
always seen, and unlike some other types of CNV, they are not usually 634 
associated with sub-retinal/sub-RPE fluid. Crucially both types of 635 
lesions may leak on FA. In a prospective case series of 17 eyes (12 636 
patients) with suspected active CNV in the context of PIC or MCP, 637 
Levison et al reported that OCTA was able to identify CNV features in 638 
15 eyes (11 patients).85 They noted that identification was easier in the 639 
3x3mm rather than the 8x8mm scan. OCTA failed to identify the CNV in 640 
two eyes: in one, the CNV was a peripaillary CNV; in the other, the CNV 641 
was obscured by a disciform scar with oedema. OCTA also provides a 642 
non-invasive way of monitoring the response to treatment (Figure 9). 643 
 644 
OCTA may change our understanding of the risks of CNV formation in 645 
posterior uveitis. In a retrospective analysis of 18 eyes with multifocal 646 
choroiditis, Zahid et al reported that the majority of eyes (16/18) had 647 
lesions in which flow could be detected by OCTA, a much higher rate of 648 
neovascularization than previously reported in a series using other 649 
forms of imaging.86 In a series of 40 eyes with multifocal choroiditis 650 
(26 patients), Cheng et al report that there were 23 active CNV cases 651 
detected on FA, of which 20 were confirmed on OCTA; the 3 which 652 
could not be confirmed had been excluded due to artefact.87 The 653 
authors also imaged 34 lesions (13 eyes), which were thought to be 654 
purely inflammatory, and noted that two of these showed flow on 655 
OCTA.87  656 
 657 
Overall OCTA would suggest that the prevalence of unrecognised 658 
neovascularisation is high in these forms of uveitis. This may have 659 
implications for treatment, such a lower threshold for treatment with 660 
anti-VEGF therapy. Furthermore these new revelations may also have 661 
relevance to some of the more acute inflammatory syndromes, which 662 
are even less commonly thought to be associated with CNV. Chen et al 663 
report on four cases of atypical MEWDS who were all noted to have 664 
type 2 neovascularization on FA and/or OCTA.88 It is likely that ready 665 
access to non-invasive angiographic assessment will reveal greater 666 
prevalence of neovascular elements in these conditions also. It is 667 
however noted that most of these cases do not progress to clinically 668 
visible CNV suggesting that a significant proportion do involute, either 669 
spontaneously or in response to immunosuppressive therapy. 670 
 671 
Birdshot uveitis 672 
In a study of OCTA findings in eight eyes (four patients) with Birdshot 673 
Chorioretinopathy (BCR), de Carlo et al reported that all eyes showed 674 
abnormalities including areas of reduced choroidal blood flow below 675 
the disrupted RPE, retinal thinning, abnormal telangiectatic vessels 676 
and an increased capillary space; the increased capillary space was 677 
most prominent temporally.89 Additionally, capillary dilatations and 678 
loops were seen in 7/8 eyes. It is worth noting that these features were 679 
present even when classic birdshot lesions were not visible on fundus 680 
photography. Roberts et al reported on 37 eyes (21 patients) with BCR 681 
vs a similar number of healthy controls, and noted that the capillary 682 
density of the full retina, and both the superficial capillary plexus and 683 
deep capillary plexus were reduced in BCR compared to the healthy 684 
controls.90 Importantly visual acuity in the BCR group was associated 685 
with a reduced capillary density, whereas FAZ area did not appear to 686 
have an effect.  687 
 688 
Behcet’s Uveitis 689 
In a prospective comparative study of FA, SD-OCT and OCTA in 690 
Behcet’s disease, Khairallah et al noted the additional value of OCTA in 691 
detecting vascular abnormalities in 25 patients (44 eyes) with Behcet’s 692 
disease.91 They reported that perifoveal microvascular changes were 693 
noted more commonly on OCTA versus FA (96% vs 59%), with specific 694 
abnormalities including disrupted perifoveal capillary arcades, retinal 695 
capillary under-perfusion, and rarefied, dilated, or shunted capillaries. 696 
These abnormalities were more commonly seen in the deep than in the 697 
superficial capillary plexus. Key differences in the Behcet’s group 698 
versus healthy controls, included increased FAZ area of the superficial 699 
and deep capillary plexi, with lower overall capillary vessel density in 700 
the deep capillary plexus. 701 
 702 
Vogt-Koyanagi-Harada Disease 703 
Clinically the early chorioretinal findings of acute VKH and multifocal 704 
central serous chorioretinopathy (CSC) may be similar.  In a study of 705 
24 patients (10 VKH, 14 CSC), Aggarwal et al evaluated the ability of 706 
OCTA to identify differences that might help distinguish these 707 
entities92. They noted that in VKH there appeared to be a true 708 
choriocapillaris flow void related to ischaemia; an important caution 709 
however is that they also noted some similar changes in the CSC group, 710 
which they ascribed to overlying SRF and PED. The elicitation of true 711 
versus artefactual flow voids will be critical to its diagnostic utility in 712 
this context. 713 
 714 
Acute Posterior Multifocal Placoid Pigment Epitheliopathy 715 
(APMPPE) 716 
The pathogenesis of APMPPE has been a controversial area ever since 717 
its original description by Gass and his proposal that it primarily 718 
targeted the RPE. Subsequent dye-based angiography has suggested 719 
that it may be primarily a choroidal vasculitis focused on the 720 
choriocapillaris. The application of OCTA may help to elucidate this.  721 
 722 
In their report Kinouchi et al described a single case of APMPPE, in 723 
which they noted that in the acute phase OCTA demonstrated dark 724 
areas with a lack of flow signals at the level of the choriocapillaris 725 
corresponding to the placoid lesions. They suggested that this was not 726 
likely to be simply due to ‘blockage’ by RPE oedema, as flow signals 727 
from the deeper choroid in these regions were still present. Similarly 728 
Salvatore et al described a single case of APMPPE in which OCTA 729 
suggested altered flow and non-perfusion in defined islands of 730 
choriocapillaris. In both cases progressive reperfusion and visual 731 
recovery occurred over time. 732 
 733 
Interestingly in their retrospective case series of five patients with 734 
APMPPE, Heiferman et al noted that choriocapillaris flow 735 
abnormalities extended beyond the visible lesions but cautioned 736 
against over-interpretation of the apparent flow voids immediately 737 
underlying the acute lesions due to the potential ‘blockage’ effect93. 738 
They did note however that after the acute phase when visualisation of 739 
the choroid improves, residual vascular abnormalities could be seen. 740 
Their finding that these vascular abnormalities may occur outside of 741 
the areas of clinically defined involvement, may suggest that the 742 
disease process in APMPPE is more extensive than currently 743 
appreciated93.  744 
 745 
 746 
Other Retinal Inflammatory Lesions 747 
OCTA may be used to identify the presence of neovascularisation in 748 
other inflammatory foci, such as isolated retinal or choroidal lesions 749 
commonly termed ‘granulomata’. Pichi et al describe a case of active 750 
Bartonella, in which OCTA of a retinal granuloma illustrated a network 751 
of vessels with microvascular proliferation within the inflammatory 752 
lesion94. Follow-up OCTA was also able to show reduction of the 753 
vascular network as the lesion responded to treatment.94 754 
 755 
OCTA in Optic Nerve Disease  756 
 757 
Glaucoma 758 
Primary open angle glaucoma (POAG) is a multifactorial optic 759 
neuropathy, possibly involving vascular dysfunction, leading to death 760 
of retinal ganglion cells and of their axons. Exploration of ocular 761 
vasculature in glaucoma has been challenging, due to various 762 
limitations in the imaging modalities; therefore, the novel 763 
developments of OCTA have raised a large interest in exploring the 764 
optic nerve microvasculature in POAG. Initial, cross-sectional studies 765 
have suggested that OCTA can be useful in evaluating the optic disc and 766 
the peripapillary retinal perfusion in glaucoma.95,96 Furthermore, these 767 
studies have shown the ability of OCTA to display attenuation of the 768 
optic nerve microvasculature in POAG, both at the optic nerve head 769 
level and at the peripapillary area, compared to normal eyes. Thus, 770 
OCTA allows non-invasive 3D visualization of the optic nerve head 771 
vasculature, from the disc surface to the lamina cribrosa, as well as 772 
quantification of optic disc perfusion.  773 
Conventional OCT has successfully provided objective and quantitative 774 
structural measurements in POAG, including evaluation of ganglion cell 775 
complex in the macular region and retinal nerve fiber layer (RNFL) 776 
thickness at peripapillary regions. However, these conventional 777 
structural OCT measurements do not seem to entirely reflect the 778 
functional outcome in glaucoma. Indeed, structural loss in glaucoma 779 
has only moderate correlation with loss of the visual field (VF) in 780 
POAG, especially at early stages. On the contrary OCTA not only reveals 781 
reduced retinal vessel density in POAG, but OCTA findings also 782 
correlate well with the disease severity and the associated visual field 783 
loss.97 These significant vascular-functional correlations in POAG, 784 
revealed by OCTA, might be explained by a pre-apoptotic status of the 785 
retinal ganglion cells at early stages. These cells and their axons may 786 
be affected only functionally at the early stages, due to the reduced 787 
vascular supply (as shown by OCTA). Their subsequent damage may 788 
translate only later into reduced visual field sensitivity and OCTA may 789 
allow the early detection of microvascular abnormalities in the course 790 
of POAG. Indeed, OCTA can disclose decreased peripapillary, optic 791 
nerve head and macular vessel densities, not only in early glaucoma 792 
with limited VF loss, but also in pre-perimetric POAG, when standard 793 
automated perimetry is still intact, despite RNFL thinning.98 OCTA may 794 
also be helpful for exploring vascular changes in secondary optic 795 
glaucomatous optic neuropathies due to neuro-ophthalmic conditions, 796 
such as increased episcleral vessels pressure occurring in carotid-797 
cavernous fistulas.99 798 
 799 
Taken together, these initial cross-sectional, observational studies 800 
suggest that OCTA may represent a potential tool for detecting 801 
vascular abnormalities in POAG, which may translate in the future into 802 
early diagnosis and improved disease monitoring. However, these 803 
preliminary studies have several inherent (technical, methodological) 804 
limitations and most importantly, do not explain yet if the 805 
microvascular attenuation in POAG is a cause or rather a consequence 806 
of the glaucomatous condition. Longitudinal studies may clarify in the 807 
future this complex temporal relationship. 808 
 809 
Non-arteritic ischemic optic neuropathy 810 
Non-arteritic anterior ischemic optic neuropathy (NAION), the most 811 
common non-glaucomatous optic neuropathy in the elderly 812 
population, is characterized by acute, painless, typically unilateral 813 
visual loss and altitudinal visual field defect, associated with optic disc 814 
swelling. NAION is possibly caused by transient hypoperfusion in the 815 
capillary bed of the optic nerve head, which is closely connected with 816 
the choroidal vasculature – explaining the high interest of its 817 
exploration with OCTA. 818 
OCTA may allow evaluation of the peripapillary microvasculature in 819 
eyes with NAION, both at the acute stage (Figure 10), and after 820 
resolution of the optic disc swelling.100 In a small pilot study, exploring 821 
eyes with NAION at the acute stage (within 1 week of visual loss), 822 
OCTA imaging revealed significant segmental and global reduction of 823 
the peripapillary vascular flow density, compared to the fellow, healthy 824 
eyes and to age-matched control eyes. In addition, OCTA may also 825 
reveal tortuous capillaries within or surrounding the optic disc in 826 
NAION, a finding clinically described as pseudoangiomatous 827 
hyperplasia101. It is not clear yet if OCTA may be useful for the 828 
longitudinal follow-up in NAION, but preliminary data suggests that 829 
OCTA may reveal spontaneous, partial recovery of peripapillary 830 
vascular flow densities during the natural course of the disease, in line 831 
with the limited improvement of the visual function.100 In addition, 832 
OCTA may also have the ability to evaluate progression of the disease, 833 
i.e. from an infra-clinical, incipient stage of NAION to its full-blown 834 
clinical picture.100 OCTA may therefore have a potential role in 835 
monitoring the evolution of NAION. 836 
 837 
However, OCTA has specific limitations in the evaluation of NAION. The 838 
reduction of the flow density at different layers in NAION may not 839 
reflect a primary ischemic process, but rather ma be the result of 840 
compressive oedema, or of imaging artefacts (signal attenuation by 841 
blood and/or oedema).  842 
 843 
Optic neuritis, multiple sclerosis and optic atrophy 844 
OCTA has been used for the evaluation the optic nerve head 845 
microvasculature in other neuro-ophthalmic conditions causing either 846 
true or pseudo-optic disc oedema (idiopathic intracranial 847 
hypertension, Leber’s hereditary optic neuropathy) or, at later stages, 848 
optic disc atrophy (after optic neuritis, NAION, or in autosomal 849 
dominant optic atrophy).101 Optic disc oedema, irrespective of its 850 
origin, may be associated with vessel tortuosity and dilated prelaminar 851 
capillary network on OCTA, but the magnitude of the associated 852 
vascular dropout may depend on the nature of the optic nerve 853 
condition and its severity. Optic disc oedema related to idiopathic 854 
intracranial hypertension may be associated with relatively preserved 855 
peripapillary microvasculature in its early stages (Figure 2). Further 856 
longitudinal studies are needed to assess the natural history of OCTA 857 
findings in optic disc oedema. 858 
Patients with multiple sclerosis (MS) who had previous episodes of 859 
optic neuritis display a reduced peripapillary and parafoveal vascular 860 
flow index, compared to healthy controls, as well as compared to 861 
patients with MS without previous optic neuritis attacks.102,103 862 
Interestingly, even in absence of optic neuritis attacks, patients with 863 
defined MS display a reduced vascular flow with OCTA, compared to 864 
controls.102,103 In patients with optic neuritis, OCTA may display 865 
residual microvascular abnormalities of the optic nerve and the 866 
macula, despite recovery of visual function after treatment.103 867 
 868 
OCTA in Anterior Segment Disease  869 
 870 
Angiography for the anterior segment has a variety of clinical 871 
applications, ranging from the evaluation of scleral inflammatory 872 
disorders, to the assessment of corneal vascularization. Currently, the 873 
assessment of the anterior segment vasculature is constrained to 874 
invasive angiography techniques using FA or ICGA. However, invasive 875 
angiography techniques expose patients to potential adverse reactions. 876 
Thus, imaging and evaluation of corneal vascularization has been 877 
limited, despite its prevalence and potential sight-threatening effects. 878 
Also, significant time and preparation is required before each ICGA or 879 
FA imaging session, while some patients may not be suitable for this 880 
procedure at all, due to various contraindications. Thus there is an 881 
increasing role for OCTA for the anterior segment104.  882 
 883 
The main advantage of OCTA for the anterior segment is that images 884 
are rapidly acquired using a non-contact technique.105 While the split-885 
spectrum amplitude-decorrelation angiography (SSADA) system has 886 
been most commonly described for the anterior segment, other 887 
spectral domain and swept source OCTA systems have also been 888 
successfully adapted for the anterior segment.106 However, it is 889 
important to note that current OCTA systems are not specifically 890 
designed for the anterior segment but may be adapted to assess the 891 
cornea or iris vasculature.105 Thus there are several limitations such as 892 
the inability to demonstrate vessel leakage, and a limited field of view 893 
compared to the FA and ICGA.107 Moreover, as the lens had to be 894 
relatively close to the surface of the cornea for the vessels to be in 895 
focus, image acquisition was relatively easier in the temporal 896 
quadrants compared to the nasal scans. Nonetheless, it has been 897 
reported that the OCTA adapted for the cornea was comparable to 898 
ICGA for measurement of the area of corneal vascularization in one 899 
pilot clinical study.108 900 
 901 
Similar to the OCTA for the retina and posterior segment, there are 902 
several points to note when interpreting OCTA scans for the anterior 903 
segment. First, image distortions may occur due to patient movement, 904 
inclinations of the scanning plane relative due to the corneal surface. 905 
Fortunately, as each non-contact scan only requires 3-4 seconds to 906 
complete, patients are usually able to tolerate multiple scans to ensure 907 
a good quality image is achieved. Second, image artefacts and loss of 908 
signal may occur in areas of dense scarring, and be compounded by the 909 
coronal reconstruction of scans. Future improvements to the software 910 
and optimization for the anterior segment may further improve the 911 
image resolution, before which a clinician may choose to perform ICGA 912 
in eyes with concomitant dense corneal scarring. Third, the OCTA 913 
systems for the anterior segment used do not come with an in-built 914 
motion correction for ocular saccades or micro-movements. It also 915 
does not carry an eye-tracking system with registration, which is 916 
required for comparisons in follow-up scans. Nonetheless, with the 917 
help of adjunct image analysis software, it has been found to be 918 
potentially useful for serial scans and follow-up in various clinical 919 
indications. 920 
 921 
While recognizing the current limitations of OCTA systems, there are 922 
still a wide variety of potential clinical applications for delineating the 923 
vasculature of the anterior segment (Figure 11).99 These include 924 
assessment of graft vascularization with prognostication for graft 925 
rejection, evaluation of new anti-angiogenic treatments for corneal 926 
vascularization, studying limbal vasculature associated with limbal 927 
stem cell deficiency, or even evaluation of bleb vascularity and 928 
morphology after glaucoma surgery (Figure 11). The ability to provide 929 
high-resolution scans of the cornea with accompanying information on 930 
the depth of abnormal vasculature, is useful for planning for 931 
procedures such as lamellar keratoplasty and fine-needle diathermy; 932 
or evaluation of peripheral corneal infiltrates or melts with the 933 
adjacent inflamed sclera and limbal vessels. Moreover, while the 934 
presence of FA or ICGA leakage influences clinical management for 935 
retinal or choroidal pathology, in the anterior segment leakage blocks 936 
vessel delineation and adds limited clinical information. On the other 937 
hand, the absence of vascular flow may be a more useful clinical sign, 938 
for example in the assessment of peripheral ulcerative keratitis, a sign 939 
which is often obscured by the leakage or extravasation of dye. The 940 
progression of corneal melting and the need for systemic 941 
immunosuppression in such severe inflammatory conditions is usually 942 
preceded by vasculitis and vaso-occlusion of the limbal vessels; while 943 
recanalization and new capillary formation may indicate response to 944 
treatment. Thus, OCTA has the potential to play an important role in 945 
detecting progression, prognostication and the management of these 946 
corneoscleral destructive diseases, which requires further studies in 947 
these specific conditions for confirmation. 948 
 949 
Other novel areas of interest 950 
 951 
Other upcoming applications of OCTA include the visualisation of the 952 
middle retinal plexus, the peri-papillary radial plexus as well as 953 
changes within the choriocapillaris and large choroidal vessels, 954 
previously not adequately visualized using conventional angiography; 955 
however the clinical significance of changes is unclear. The 956 
development of variable inter-scan time acquisition protocols (VISTA) 957 
may also allow variable flow rates (both slow and fast) to be detected 958 
in future OCTA platforms109.  959 
 960 
Summary  961 
 962 
Optical coherence tomography angiography (OCTA) has emerged as a 963 
novel, non-invasive imaging modality that allows the detailed study of 964 
flow within the vascular structures of the eye. This new technology, 965 
still in its infancy, has the potential to improve the diagnosis and 966 
monitoring of various vascular and inflammatory diseases by imaging 967 
vascular networks in greater detail than ever before. In addition, to the 968 
retina, OCTA can be used also in the anterior segment and optic nerve. 969 
Keeping in mind the current limitations of this technology, future 970 
technical improvements and increased validation of this promising 971 
imaging modality is necessary to improve the clinical application of 972 
OCTA.  973 
Legends 974 
 975 
Figure 1: OCTA of a single normal eye showing variations in the 976 
scan area and algorithms. Cross sectional OCTA images of the 977 
superficial vascular plexus segmentation (top row) and deep vascular 978 
plexus (third row). En face OCTA images of the superficial vascular 979 
plexus segmentation (second row) and deep vascular plexus (bottom 980 
row). A: An 8x8 mm scan taken with the AngioVue RTVue XR Avanti 981 
processed with the SADA algorithm; B: A 6x6 mm scan taken with the 982 
Angioplex CIRRUS HD-OCT Model 5000 processed with the OMAG 983 
algorithm; C: A 3x3 mm scan taken with DRI-OCT Triton swept source 984 
OCT processed with the OCTA-RA algorithm. On the automated 985 
segmentation of the deep vascular plexus of both the Angiovue and 986 
Angioplex, some projection artefact from the superficial layer is 987 
observed. 988 
 989 
Figure 2: A summary of an approach to OCTA interpretation. 990 
 991 
Figure 3: Examples of common artefacts seen on OCTA. A: Motion 992 
artefact seen by black vertical lines caused by blinking (yellow 993 
arrowhead) and eye movements (green arrowhead). B: An example of a 994 
projection artefact (yellow boxes) of the superficial vessels seen in the 995 
deep vascular plexus segmentation. Comparing the deep vascular plexus 996 
segmentation, all the projection artefact seen can be accounted for by 997 
the more superficial vessels (green boxes). C: Unmasking artefact seen as 998 
an area of high flow (middle of crosshairs) on en face OCTA (left), cross-999 
sectional OCTA (middle) showed a focal area of atrophy with underlying 1000 
hyper-transmission of the signal (yellow arrow). Area of high flow on en 1001 
face OCTA can be accounted for by an area of atrophy causing the 1002 
underlying choroidal vessels to be seen as an area of unmasking artefact. 1003 
This is confirmed by the corresponding area of hypo-autofluorescence 1004 
seen on fundus autofluorescence (right). D: Enface OCTA (left) 1005 
corresponding to cross sectional OCTA (middle top) showing a straight 1006 
segmentation line that does not capture polyps (blue arrow) seen at the 1007 
peak of the pigment epithelial detachment. Alternatively, when using the 1008 
RPE fit segmentation the area of polyps (orange arrow) are then seen on 1009 
en face OCTA 1010 
 1011 
Figure 4: Multimodal images including OCTA images of the 3 1012 
subtypes of neovascular age-related macular degeneration. 1013 
(CFP=colour fundus photo, FA=fundus fluorescein angiography, 1014 
ICGA=indocyanine green angiography, OCTA= topical coherence 1015 
tomography angiography, OCT= optical coherence tomography) A: Type 1016 
1 neovascularisation (NV) (yellow arrows) with a vascularised pigment 1017 
epithelial detachment seen on CFP, stippled hyperfluorescence and late 1018 
leakage on FA, a plaque on ICGA and a vascular network seen on en face 1019 
OCTA with a corresponding area of abnormal flow seen under the RPE on 1020 
cross sectional OCTA. B: Type 2 NV (green arrows) with a greyish 1021 
membrane seen on CFP, early lacy hyperfluorescence with late leakage 1022 
seen on FA and a vascular network seen on en face OCTA with abnormal 1023 
flow seen above the RPE on cross-sectional OCTA. C: Type 3 NV (blue 1024 
arrows) seen with associated atrophy on CFP, pinpoint leakage on FA 1025 
with an area of abnormal flow on en face OCTA corresponding to a linear 1026 
area of abnormal flow in the deep retina seen on cross-sectional OCTA 1027 
seen below a large patch of geographic atrophy. 1028 
 1029 
Figure 5: Multimodal images including OCTA images of mixed 1030 
subtypes of neovascular age-related macular degeneration. 1031 
(CFP=colour fundus photo, FAF= fundus autofluorescence, FA=fundus 1032 
fluorescein angiography, ICGA=indocyanine green angiography, OCTA= 1033 
topical coherence tomography angiography, OCT= optical coherence 1034 
tomography). A: Type 1 neovascularisation (NV) with polypoidal 1035 
choroidal vasculopathy. Polyps (blue arrows) seen as orange nodules on 1036 
CFP, focal leakage on FA, clusters of hypercyanescence on ICGA and a 1037 
focal area of increased flow surrounded by a halo of decreased flow 1038 
signal on en face OCTA with a corresponding area of abnormal flow 1039 
directly under the RPE seen on cross sectional OCTA. An associated 1040 
branching vascular network or type 1 NV (orange arrows) seen as 1041 
stippled hyperfluorescence on FA, a plaque on ICGA and a vascular 1042 
network on OCTA corresponding to shallow, irregular pigment epithelial 1043 
detachment containing abnormal flow seen on cross sectional OCTA. B: A 1044 
mixed type 2 and type 1 NV with the subretinal type 2 component (yellow 1045 
circles and arrow) and the sub-retinal pigment epithelial type 1 1046 
component (green circles and arrows).   1047 
 1048 
Figure 6: OCTA images showing different  neovascularisation (NV) 1049 
responses to treatment with intravitreal anti- vascular endothelial 1050 
growth factor therapy (IVT). A: En face OCTA (top row) shows after 1 1051 
IVT, there is reduction in the overall size of the type 2 NV with the 1052 
regression of the smaller peripheral anastomosis leaving the larger 1053 
calibre vessel trunks. After 3 IVTs the lesion size remains stable with the 1054 
persistence of the larger calibre vessel trunks with a reduction in the 1055 
dark halo surrounding the vascular lesion. Corresponding cross-sectional 1056 
OCTA (second row) that show the reduction in the area of abnormal flow 1057 
(red overlay) during the course of treatment. B: Enface OCTA with color-1058 
coded density mapping showing the reduction in size of the type 1 NV 1059 
(red) from baseline and after 6 IVTs with corresponding cross-sectional 1060 
OCTAs showing a reduction in abnormal flow (red overlay) from 1061 
baseline. 1062 
 1063 
Figure 7: OCTA features in diabetic retinopathy. A: An eye with severe 1064 
non-proliferative diabetic retinopathy with microaneurysms 1065 
surrounding the fovea as seen on fluorescein angiography (left) and the 1066 
corresponding 6x6 (middle) and 3x3 (right) en face OCTA of the 1067 
superficial segmentation. An enlarged foveal avascular zone (FAZ) is also 1068 
noted (yellow arrows). B: An eye with diabetic macula oedema and an 1069 
enlarged FAZ (green arrow) with disruption of the normal vasculature 1070 
inferiorly as seen on enface OCTA with superficial segmentation (left) 1071 
and corresponding cross-sectional OCTA middle (top) and similarly with 1072 
deep segmentation (right and middle bottom). Both the cystic spaces 1073 
from diabetic macula oedema and areas of non-perfusion are seen as 1074 
dark areas on the deep segmentation en face OCTA. 1075 
 1076 
Figure 8:OCTA features of branch retinal vein occlusion. A: Fundus 1077 
fluorescein angiography (FA) showing an ischaemic branch retinal vein 1078 
occlusion with neovascularisation and areas of capillary non-perfusion. 1079 
B: The areas of non-perfusion corresponding to the FA (yellow box) are 1080 
seen clearly on en face OCTA. C: An area of neovascularisation leaking on 1081 
FA (green box) is seen on en face OCTA as a small vascular tuft of high 1082 
flow growing into the posterior hyaloid as seen on cross sectional OCTA. 1083 
 1084 
Figure 9: OCTA identifies neovascular membrane secondary to 1085 
puntate inner chorioretinopathy (PIC). A: En face OCTA shows an area 1086 
of absent flow (yellow circle) on the choriocapillary segmentation seen to 1087 
correspond with a hyper-reflective inflammatory lesion (yellow arrow) 1088 
on cross sectional OCTA with absent flow. B: Another PIC lesion seen on 1089 
colour fundus photo (top left), the corresponding en face OCTA shows a 1090 
secondary choroidal neovascularisation (CNV) (blue circle), with the 1091 
corresponding cross sectional OCTA showing an area of abnormal flow 1092 
(blue arrow) on the hyper-reflective inflammatory lesion. After 1 1093 
intravitreal anti- vascular endothelial growth factor therapy (IVT) 1094 
(bottom row), there is regression of the CNV seen on both en face and 1095 
cross sectional OCTA (blue circle and arrow). 1096 
 1097 
Figure 10. OCTA findings in a patient with non-arteritic ischemic 1098 
optic neuropathy and ipsilateral visual loss. The sectorial optic disc 1099 
swelling (A), is associated on OCTA (AngioVue, Optovue) with tortuous 1100 
radial peripapillary capillaries and vascular dropout in the optic nerve 1101 
head (B). Optic nerve head swelling in a patient with idiopathic 1102 
intracranial hypertension and preserved visual function (C). Despite the 1103 
severe optic disc swelling and peripapillary hemorrhages (C), OCTA 1104 
evaluation (AngioVue, Optovue), discloses only limited vascular dropout 1105 
in the optic nerve head region (D & E).  1106 
 1107 
Figure 11. Optical coherence tomography angiography of the 1108 
cornea.  A. Fungal keratitis with chronic inflammation and corneal 1109 
vascularisation. B. Optical coherence tomography angiography imaging 1110 
may be useful to guide fine needle diathermy and anti-VEGF therapy to 1111 
reduce corneal vascularisation before corneal transplantation, and risk 1112 
of corneal graft rejection. C. Interstitial keratitis with deep corneal 1113 
vascularisation. D. Optical coherence tomography angiography reveals 1114 
deeper vessels not obvious on slit-lamp microscopy.    1115 
 1116 
 1117 
Table 1: Comparison of optical coherence tomography angiography 1118 
(OCTA) versus conventional angiography such as fundus fluorescein 1119 
angiography (FA) and indocyanine green angiography (ICGA). 1120 
 1121 
Table 2: Comparison of four current commercially available optical 1122 
coherence tomography angiography (OCTA) platforms and their various 1123 
specifications (Information up to date as of January 2017). 1124 
 1125 
Table 3: Multimodal characteristics of atrophic age-related macular 1126 
degeneration (AMD) and subtypes of neovascular AMD 1127 
 1128 
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Table 1: Comparison of optical coherence tomography angiography (OCTA) versus conventional angiography such as fundus fluorescein 
angiography (FFA) and indocyanine green angiography (ICGA). 
 
 
OCTA 
 
FFA ICGA 
New technology not validated Well validated technology 
Correlation to multi-modal imaging and 
histology  
Well validated technology
Correlation to multi-modal imaging and 
histology 
Non-invasive, no need for dye Invasive, need for dye risk of anaphylaxis Invasive, need for dye risk of anaphylaxis
Rapid acquisition time 
Interpretation may require more time 
Time-consuming to perform 
Image viewing may be faster 
Time-consuming to perform
Image viewing may be faster 
Provides depth information of both retinal 
and choroidal vasculature 
Able to segment various layers 
No information about individual layers
 
Retina imaged in entirety 
No information about individual layers
 
Choroid imaged in entirety 
Able to image through blood 
Artifacts may hamper interpretation 
Blockage from blood
Less artifact 
Able to penetrate blood 
Less artifact 
Detection of flow but not leakage Detection of leakage and activity Detection of leakage and activity
High resolution down to capillaries in the 
retina 
Lower resolution, able to image large retinal 
vessels but not capillaries 
Able to image large choroidal vessels but not 
choriocapillaries 
Small field of view Wide field option available Wide-field option available
No stereoscopic function Stereoscopic option Stereoscopic option
No dynamic video function Video function available Video function available
 
Table 2: Comparison of four current commercially available optical coherence tomography angiography (OCTA) platforms and their 
various specifications (Information up to date as of January 2017). 
Specifications AngioVue Angioplex Spectralis OCTA SS OCT Angio Angioscan
 
OCT platform AngioVue RTVue 
XR Avanti 
CIRRUS HD-OCT Model 
5000 
Spectralis OCT-2 DRI-OCT Triton 
swept source OCT 
RS-3000 Advance
Imaging company Optovue Carl Zeiss Meditec, Inc Heidelberg 
Engineering 
Topcon Corporation Nidek
Place of origin Fremont, California, 
USA 
Dublin, California, USA Heidelberg, Germany Tokyo, Japan Gamagori, Aichi, 
Japan 
Scanning speed 70,000 scans/sec 68, 000 scans/sec 85,000 scans/sec 100,000 scans/sec 53, 000 scans/sec
Scanning volume  304x304 A scans 245x245, 350x350
A scans 
512x512 A scans 320x320, 512x512 A 
scans 
256x256 A scans
Algorithm Split-spectrum 
amplitude-
decorrelation 
angiography 
(SSADA) 
Optical coherence 
microangiography-
complex (OMAG) 
Probalistic Model that 
predicts whether a 
voxel contained flow or 
not. 
OCTA- Ratio Analysis 
(full spectrum 
amplitude) 
Complex difference 
(full spectrum 
amplitude) 
Type of algorithm Amplitude Amplitude+phase Probablistic model Amplitude Amplitude +phase
 
Scan area (macula) 
 
3x3, 6x6, 8x8 mm 3x3, 6x6, 8x8 mm 
 
3x3 mm with (5.7 x 
5.7) µm/px 
3x3, 4.5x4.5, 6x6, 9x9 
mm  
3x3-9x9mm (12x9 
montage) 
Optical Resolution 
• Axial 
• Lateral  
• Light source 
• Axial imaging depth 
 
3μm 
15μm 
840nm 
2-3mm 
5μm 
15μm 
840nm 
2mm 
 
7μm 
14μm 
880nm 
1.9mm 
8μm 
20μm 
1050nm 
2.6mm 
7μm 
20μm 
880nm 
2.1mm 
Automated segmentation 
options 
Superficial retinal 
capillary plexus 
Deep retinal 
capillary plexus 
Outer Retina 
Choriocapiliaries 
Retina depth encoded
Vitreo-retinal interface
Superficial retina 
Deep retina 
Avascular layer 
Choriocapillaris 
Choroid 
4 presets matching 
vasculature in retinal 
nerve fibre layer, 
ganglion cell layer and 
bracketing the inner 
nuclear layer 
3 presets to cover the 
retina (Superficial, 
Deep Vascular Plexus 
and Avascular Layer) 
 
Superficial vascular 
plexus 
Deep vascular plexus 
Outer retina 
Choriocapillaris 
 
Superficial retinal 
layer 
Deep retinal layer 
Avascular 
Choriocapillaris 
Color coding of 
segmentations 
Yes Yes Yes  Yes Yes
Cross sectional OCTA 
image 
Yes Yes Yes Yes No
Eye tracker Software update for 
older models 
Available with 
newer models 
Yes (Fast Trac) Yes (TruTrack) Yes (Smart Track) Yes
Motion correction  Yes (Motion 
Tracker) 
N/A Covered by TruTrack Yes Yes (real-time SLO 
eye tracking) 
Projection artifact 
removal 
Yes Yes Under development Yes Yes
Optic nerve OCTA Yes Yes Yes Yes Yes
Anterior segment OCTA 
function 
Prototype Under development No No Yes
Quantitative analysis Yes Yes Under development Yes (prototype) Yes
Comparative follow-up 
function 
Yes Yes Yes Yes No
 
Table 3: Multimodal characteristics of atrophic age-related macular degeneration (AMD) and subtypes of neovascular AMD 
 
 
 
Imaging 
modality 
 
Atrophic AMD Neovascular AMD 
Type 1 NV 
 
BVN+PCV Type 2 NV Type 3 NV 
CFP Area of depigmentation
 
Blood, exudation, 
PED 
Blood, exudation PED, orange 
nodule 
Blood, exudation, 
greyish membrane
Pigmentary changes, 
exudation, blood 
FAF Hypoautofluorescence area 
Hyperfluorescent border Variable  
 
Variable Variable Not seen 
 
FA  
Window defect 
Stippled 
hyperfluorescence 
with late diffuse 
leakage 
Stippled hyperfluorescence with 
late diffuse leakage in the BVN 
Early lacy pattern 
with late leakage 
Focal areas of early 
leakage with right 
angled vessels 
ICGA Hypercyanescence in area of 
atrophy due to a window defect 
Hypercyanescent 
plaque  
Focal areas of hypercyanascence 
(polyps) with adjacent plaque 
Not well defined Retina choroidal 
anastomosis 
 
OCT 
 
Loss of the hyperreflective RPE band
and outer retinal layers 
Multi-layered PED 
Subretinal fluid 
and subretinal 
hyperreflective 
material 
 
Focal elevated peaked PED 
(polyp) associated serous PED or 
shallow irregular PED (BVN) 
Subretinal fluid 
Subretinal hyper-
reflective material 
(SHRM)  
Subretinal fluid 
Linear hyperreflective 
structure in the outer 
retina 
Intraretinal fluid 
Cross 
sectional 
OCTA 
High flow signal in the choroid 
beneath the area of RPE atrophy 
Intrinsic flow 
signal within the 
PED 
Focal areas of flow within the 
PED with high flow signal within 
BVN 
Intrinsic flow seen 
within SHRM 
Intrinsic linear flow 
within the 
hyperreflective 
structure 
En face 
OCTA 
Unmasking artefact with the 
atrophic area showing an increased 
flow signal  
A tangle of vessels Variable flow within polyps BVN 
seen as a tangle of vessels 
A tangle of vessels High flow tuft
AMD=age-related macula degeneration, NV=neovascularization, BVN=branching vascular network, CFP=color fundus photo, 
PED=pigment epithelial detachment, FAF=fundus autofluorescence, FA=fluorescein angiography, ICGA=indocyanine green angiography, 
OCT=optical coherence tomography, OCTA= optical coherence tomography tomography,  
 
